Vinflunine for Bladder Cancer Treatment
Author Information
Author(s): Culine S, Theodore C, De Santis M, Bui B, Demkow T, Lorenz J, Rolland F, Delgado F-M, Longerey B, James N
Primary Institution: CRLC Val d'Aurelle, Montpellier, France
Hypothesis
Vinflunine is effective as a second-line therapy for bladder cancer patients who have progressed after first-line platinum-based chemotherapy.
Conclusion
Vinflunine shows clinically relevant activity with manageable toxicity in patients with bladder cancer who have failed prior platinum-based chemotherapy.
Supporting Evidence
- Nine out of 51 patients responded to vinflunine, yielding an overall response rate of 18%.
- 67% of patients achieved disease control (partial response + stable disease).
- The median duration of response was 9.1 months.
- The median progression-free survival was 3.0 months.
- The median overall survival was 6.6 months.
Takeaway
Vinflunine is a medicine that helps some people with bladder cancer when other treatments don't work. It can make the cancer smaller and is usually safe to use.
Methodology
This was an open-label, multicentre, noncomparative phase II trial assessing vinflunine's efficacy in patients with advanced transitional cell carcinoma of the bladder.
Potential Biases
Potential bias due to the open-label design and lack of a control group.
Limitations
The study had a small sample size and focused only on patients who had previously received platinum-based chemotherapy.
Participant Demographics
The study included 51 patients, predominantly male (80%), with a median age of 63 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 8.4–30.9%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website